These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 24982338)

  • 1. TYRO3 as a potential therapeutic target in breast cancer.
    Ekyalongo RC; Mukohara T; Funakoshi Y; Tomioka H; Kataoka Y; Shimono Y; Chayahara N; Toyoda M; Kiyota N; Minami H
    Anticancer Res; 2014 Jul; 34(7):3337-45. PubMed ID: 24982338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer.
    Cohen B; Shimizu M; Izrailit J; Ng NF; Buchman Y; Pan JG; Dering J; Reedijk M
    Breast Cancer Res Treat; 2010 Aug; 123(1):113-24. PubMed ID: 19915977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of simultaneous knockdown of HER2 and PTK6 on malignancy and tumor progression in human breast cancer cells.
    Ludyga N; Anastasov N; Rosemann M; Seiler J; Lohmann N; Braselmann H; Mengele K; Schmitt M; Höfler H; Aubele M
    Mol Cancer Res; 2013 Apr; 11(4):381-92. PubMed ID: 23364537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. shRNA-mediated silencing of ZFX attenuated the proliferation of breast cancer cells.
    Yang H; Lu Y; Zheng Y; Yu X; Xia X; He X; Feng W; Xing L; Ling Z
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):569-76. PubMed ID: 24448637
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Saito T; Itoh M; Tohda S
    Anticancer Res; 2022 Apr; 42(4):1757-1761. PubMed ID: 35346994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [siRNA-cyclin D1 inhibit cell proliferation in breast cancer MCF-7 cell line].
    Jiang L; Chen RS; Li JC
    Fen Zi Xi Bao Sheng Wu Xue Bao; 2006 Apr; 39(2):118-22. PubMed ID: 16944582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SiRNA inhibition of ER-alpha expression reduces KGF-induced proliferation of breast cancer cells.
    Zang XP; Pento JT
    Anticancer Res; 2008; 28(5A):2733-5. PubMed ID: 19035303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype.
    Veenstra C; Karlsson E; Mirwani SM; Nordenskjöld B; Fornander T; Pérez-Tenorio G; Stål O
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1845-1856. PubMed ID: 31025094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.
    Hurvitz SA; Kalous O; Conklin D; Desai AJ; Dering J; Anderson L; O'Brien NA; Kolarova T; Finn RS; Linnartz R; Chen D; Slamon DJ
    Breast Cancer Res Treat; 2015 Feb; 149(3):669-80. PubMed ID: 25663547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic role of TYRO3 receptor tyrosine kinase in the progression of pancreatic cancer.
    Morimoto M; Horikoshi Y; Nakaso K; Kurashiki T; Kitagawa Y; Hanaki T; Sakamoto T; Honjo S; Umekita Y; Fujiwara Y; Matsura T
    Cancer Lett; 2020 Feb; 470():149-160. PubMed ID: 31765735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer.
    McCleland ML; Adler AS; Shang Y; Hunsaker T; Truong T; Peterson D; Torres E; Li L; Haley B; Stephan JP; Belvin M; Hatzivassiliou G; Blackwood EM; Corson L; Evangelista M; Zha J; Firestein R
    Cancer Res; 2012 Nov; 72(22):5812-23. PubMed ID: 23139210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy.
    Zhao H; Faltermeier CM; Mendelsohn L; Porter PL; Clurman BE; Roberts JM
    Oncotarget; 2014 Dec; 5(24):12704-14. PubMed ID: 25587029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
    Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. si-RNA-Mediated Silencing of ADRBK1 Gene Attenuates Breast Cancer Cell Proliferation.
    Zhang C; Chen X; Li Y; S W A H; Wu J; Shi X; Liu X; Kim S
    Cancer Biother Radiopharm; 2014 Oct; 29(8):303-9. PubMed ID: 25279970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small interfering RNA-directed targeting of RON alters invasive and oncogenic phenotypes of human hepatocellular carcinoma cells.
    Cho SB; Park YL; Song YA; Kim KY; Lee GH; Cho DH; Myung DS; Park KJ; Lee WS; Chung IJ; Choi SK; Kim KK; Joo YE
    Oncol Rep; 2011 Dec; 26(6):1581-6. PubMed ID: 21874262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling.
    Brennan K; McSherry EA; Hudson L; Kay EW; Hill AD; Young LS; Hopkins AM
    Oncogene; 2013 May; 32(22):2799-804. PubMed ID: 22751120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
    Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
    Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor binding protein-3 induces G1 cell cycle arrest with inhibition of cyclin-dependent kinase 2 and 4 in MCF-7 human breast cancer cells.
    Kim HS; Lee WJ; Lee SW; Chae HW; Kim DH; Oh Y
    Horm Metab Res; 2010 Mar; 42(3):165-72. PubMed ID: 19960406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of specific silencing of EMMPRIN on the growth and cell cycle distribution of MCF-7 breast cancer cells.
    Yang XQ; Yang J; Wang R; Zhang S; Tan QW; Lv Q; Meng WT; Mo XM; Li HJ
    Genet Mol Res; 2015 Dec; 14(4):15730-8. PubMed ID: 26634540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.